文档介绍：子痫前期患者检测凝血、抗凝和纤溶实验室指标的价值分析
[摘要]目的 觀察凝血、抗凝及纤溶指标在不同程度妊娠期高血压病患者中的水平变化及对母婴结局的影响。方法 回顾性分析2017年8月~2018年8月在深圳市妇幼保健院分娩的130time (APTT), antithrombin-Ⅲ (AT-Ⅲ), D-dimer (D-D), tissue plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), fibrinogen (FIB), and fibrinogen degradation products (FDP) levels of gestational hypertension in different periods were analyzed. The occurrence of adverse maternal outcomes in pregnancy-induced hypertension women such as placental abruption, postpartum hemorrhage, fetal growth restriction, intrauterine distress, premature delivery, and stillbirth was recorded. Results The PT and APTT in pregnant women with gestational hypertension were shorter than those in healthy pregnant women, the level of AT-Ⅲ was lower than that in the healthy pregnant women, and the levels of D-D, t-PA, PAI-1, FIB and FDP were higher than those in the healthy pregnant women, with statistically significant differences (P<). In pregnant women at different stages of hypertensive gestation, the PT and APTT in severe preeclampsia were shorter than those in mild preeclampsia and gestational hypertension, the level of AT-Ⅲ in severe preeclampsia was lower than that in mild preeclampsia and gestational hypertension, and the levels of D-D, PAI-1, FDP and FIB were higher than those in mild preeclampsia and gestational hypertension, with statistically significant differences (P<). The level of maternal AT-Ⅲ in patients with adverse maternal and infant outcomes was lower than that without adverse maternal outcome, the level of PAI-1 was higher compared with that without adverse outcomes, with statistically significant differences (P<). Conclusion Women with pregnancy-induced hypertension, especially in preeclampsia, is abnormally hypercoagulable. Early detection of blood coagulation, anticoagulation and fibrinolysis can prevent the occurrence of adverse maternal and child outcomes. [Key words] Coagulation indicator; Fibrinolysis indicator;